Silo prime3/10/2023 Again utilizing the 505(b) pathway, the timeline for approval can be considerably shortened and millions of dollars saved. Silo's path to developing and bringing to market better drugs includes finding more effective ways to treat conditions like Alzheimer's, Parkinson's, Multiple Sclerosis, Rheumatoid Arthritis, and Stress-Induced Psychiatric Disorders. And not just for its initial Fibromyalgia indication. They are advancing research targeting treatment for several unique indications, with data supporting that traditional pharmaceuticals combined with psychedelics can be an effective and safe therapeutic. As noted, SILO isn't a single-shot drug company. Multiple Indications In The Treatment Crosshairs And with only about 3.14 million outstanding shares reported at the end of last quarter, product development updates could positively benefit investors from a supply and demand perspective. Thus, while its recent run is impressive, there could be considerably more room to run for this thinly traded stock. That adds to revenue-generating potential and helps expose a valuation disconnect between share price and blue-sky opportunities. Moreover, the value proposition is enhanced with patients wanting alternatives to side-effect and addictive-prone pharmaceutical regimens leading to potential partnerships, grants, and private funding to accelerate development. That could provide first-to-market opportunities in several billion-dollar markets. SILO is taking that approach further by adding the pharmaceutical composition to the opportunity. Remember, too, that psychedelics are already being evaluated to treat various indications. Each trial that moves forward is another milestone reached more importantly, they present additional catalyst potential. Once licensed, an asset is researched, funded, and if promising, a study design is created to show how that drug can better treat patients. Cutting the time and cost, SILO identifies and licenses assets amenable to combination therapy. Doing so may not be as demanding on the regulatory front as many might expect. Silo Pharma expects to provide better therapeutic value to patients by merging traditional therapeutics with psychedelics to treat people suffering from symptoms associated with PTSD, Parkinson's, and Alzheimer's disorders. Keep in mind that SILO isn't targeting obscure indications they are focused on developing more effective treatments for neurological disorders where the standard of care falls short. Not only could that expedite approvals, but it can also help revenues to ramp quickly. Those drug development programs could also benefit from expedited marketing approval pathways through 505(b) applications. And those contributions target a generation of patients more receptive than ever to trying alternative treatment methods over prescription compounds and opioids. Still, while promising on the Fibromyalgia front, SILO has more pipeline firepower. SILO's drug candidate provides an excellent shot on goal to treat those indications. A better drug could also fill current gaps to help treat sleep difficulties, fatigue, mood disorders, and problems with memory and concentration attributable to consistent and often relentless Musculoskeletal pain. While narcotics can ease chronic pain, more effective, less invasive, and non-addictive ways to alleviate pain associated with connective tissues throughout the body, including muscles, ligaments, and tendons, are needed. For patients with the debilitating condition, better treatment is needed. According to Fortune Business Insights, the Fibromyalgia treatment market is projected to grow from $764.1 million in 2020 to over $1.4 billion in 2027, representing a CAGR of 9.2% during the next five years. The dollar potential for an effective treatment is significant. With Fibromyalgia affecting about 4 million American adults or about 2% of the adult population, signs of a more effective treatment could fuel further interest in SILO. Pre-clinical data has shown that the Z-pod can hold and distribute ketamine in a time-released manner, putting a potential treatment for Fibromyalgia in the crosshairs as an initial indication. One particular combination therapy is being evaluated in a collaborative effort with joint venture partner Zylö Therapeutics, Inc., with SILO pursuing the clinical development of ketamine using Zylö Z-pod™ technology. Unlike traditional drug applications that often take years of reviews and millions in development costs, SILO intends to expedite the process by pursuing the 505(b)(2) regulatory pathway, saving considerable time and enormous amounts of money in that process. The news is also good in terms of progressing through the regulatory pathway. The company believes its highly constructive pre-clinical work on SP-26 offers strong support for its comprehensive pre-IND package, including showing evidence of value from its time-released ketamine delivery system.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |